A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 16 Apr 2018 According to the Genentech media release, data from this study will be presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
    • 06 Feb 2018 According to an AC Immune media release, data from the study will be present at the AAT-AD/PDTM conference 2018.
    • 16 Oct 2017 Planned End Date changed from 28 Jun 2023 to 1 Sep 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top